Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidiseds GC
Ingo Ahrens, Jonathon Habersberger, Nadege Baumlin, Hongwei Qian, Belinda K Smith, Johannes-Peter Stasch, Christoph Bode, Harald HHW Schmidt, Karlheinz Peter
Atherosclerosis | ELSEVIER IRELAND LTD | Published : 2011
OBJECTIVE: The soluble guanylate cyclase (sGC) activator Cinaciguat (BAY 58-2667) represents a novel class of drugs that selectively activate oxidised sGC. The extent of oxidised sGC depends on the patient's oxidative burden. We here describe two platelet-based assays that allow determining the extent of oxidised sGC and thus provide a basis for an individualised pharmacotherapy. METHODS/RESULTS: Platelets obtained from patients with (n=12) and without (n=12) coronary artery disease (CAD) were examined by flow cytometry (P-selectin expression), and Western blots (vasodilator associated phosphoprotein, VASP-phosphorylation). Results were compared to maximal oxidation of sGC achieved by the ox..View full abstract
Awarded by Deutsche Forschungsgemeinschaft [DFG]
This work was supported by the Deutsche Forschungsgemeinschaft [DFG AH 185/1-1 to I.A.], by the National Health and Medical Research Council of Australia [K.P, J.H., N.B., B.K.S., H.H.H.W.S.] and by the Cardiac Society of Australia and New Zealand [J.H.].